Table 1.
Patient characteristics
| N = 30 | No. | Percent |
|---|---|---|
| Age at transplant, median, year (range) | 54.5 (36-70) | - |
| Male | 15 | 50 |
| Multiple myeloma subtype | ||
| IgG | 15 | 50 |
| IgA | 9 | 30 |
| Light chain | 5 | 17 |
| Plasma cell leukemia | 1 | 3 |
| Chromosomal abnormality*1 | ||
| High risk | 13 | 45 |
| 13q deletion | 11 | 38 |
| 17p deletion | 2 | 7 |
| t(4;14) | 2 | 7 |
| Standard risk | 16 | 55 |
| β2 microglobulin, median, mg/L (range) | 4.35 (1.8-11.4) | - |
| Refractory disease*2 | 16 | 55 |
| Albumin, median, g/dL (range) | 3.7 (3.1-4.9) | - |
| Time from diagnosis to enrollment, median, month (range) |
7 (3 – 80)*3 | - |
| Prior chemotherapy | ||
| Thalidomide/dexamethasone | 14 | 46 |
| Lenalidomide-based regimen*4 | 11 | 37 |
| Vincristine/Adriamycin/dexamethasone (VAD) | 5 | 17 |
| Liposomal doxorubicin-based regimen | 3 | 10 |
| Number of prior regimens | ||
| 1 | 23 | 77 |
| ≥2 | 7 | 23 |
| Durie-Salmon Staging System*5 | ||
| 1 | 3 | 10 |
| 2 | 6 | 21 |
| 3 | 20 | 69 |
| International Staging System (ISS) | ||
| I | 8 | 27 |
| II | 16 | 53 |
| III | 6 | 20 |
*1
One patient with plasma cell leukemia was not included in the chromosomal risk classification.
*2
Disease progression during induction therapy or within 60 days of discontinuing induction therapy (prior to enrollment)
*3
One patient was diagnosed as asymptomatic myeloma 6 years prior to study enrollment and only required systemic therapy 4 months before the enrollment.
*4
Three patients received liposomal doxorubicin containing regimen.
*5
One patient with plasma cell leukemia was excluded.